{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-223699","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2022-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.000828+00:00","generated_at":"2026-06-23T22:43:03.323518+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib","bullets":["FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.","Partial hold on TakeAim Leukemia study remains under FDA Division of Hematologic Malignancies 1.","Hold lifted after FDA agreement on rhabdomyolysis management and enrollment of ≥9 patients at 200 mg emavusertib plus ibrutinib.","Preliminary clinical data update from TakeAim Lymphoma expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-223699","json":"https://secwatch.observer/filing/0001193125-22-223699.json","markdown":"https://secwatch.observer/filing/0001193125-22-223699.md","text":"https://secwatch.observer/filing/0001193125-22-223699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/0001193125-22-223699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000119312522223699/d356879d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:43:03.323518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}